

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification⁷: A61K 39/00, 48/00, A61P 31/00, 33/00, 35/00, A61K 39/385 // C07K 14/26, C12N 15/62	A1	(11) International publication number: WO 00/48628 (43) International publication date: 24 August 2000 (24.08.00)
(21) International application number: PCT/FR00/00393 (22) International filing date: 17 February 2000 (17.02.00) (30) Data relating to the priority: 99/01,917 17 February 1999 (17.02.99) FR (71) Applicant (for all designated States except US): PIERRE FABRE MEDICAMENT [FR/FR]; 45, place Abel Gance, F-921100 Boulogne-Billancourt (FR). (72) Inventors; and (75) Inventors/Applicants (US only): RENNO, Toufic [LB/FR]; Les Coulerins B1, F-74580 Viry (FR). BONNEFOY, Jean-Yves [FR/FR]; Les Noyers, F-74350 Le Sappey (FR). (74) Representatives: MARTIN, Jean-Jacques etc.; Cabinet Regimbeau, 26, avenue Kléber, F-75116 Paris (FR).		(81) Designated states: AU, BR, CA, CN, JP, MX, US, ZA, European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With the International Search Report.

As printed

(54) Title: USE OF AN ENTEROBACTERIUM PROTEIN OMPA ASSOCIATED WITH AN ANTIGEN FOR GENERATING AN ANTIVIRAL, ANTIPARASITIC OR ANTITUMORAL CYTOTOXIC RESPONSE

(54) Titre: UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE ASSOCIEE A UN ANTIGENE POUR GENERER UNE REPONSE CYTOTOXIQUE ANTIVIRALE, ANTIPARASITAIRE OU ANTITUMORALE

(57) Abstract

The invention concerns the use of an enterobacterium OmpA membrane protein, in particular of *Klebsiella pneumoniae* associated with an antigen or a hapten for preparing a pharmaceutical composition for generating or enhancing a cytotoxic T response directed against an infectious or tumor cell. The invention also concerns the use of said compounds for preventing and treating infection or cancer, in particular cancers associated with a tumoral antigen such as melanoma, and pharmaceutical compositions comprising some of said compounds.

(57) Abrégé

L'invention concerne l'utilisation d'une protéine de membrane OmpA d'entérobactérie, notamment de *Klebsiella pneumoniae*, associée à un antigène ou un haptène pour la préparation d'une composition pharmaceutique destinée à générer ou accroître une réponse T cytotoxique dirigée contre un agent infectieux ou une cellule tumorale. L'invention comprend l'utilisation de ces composés pour la prévention et le traitement d'infection ou de cancer, notamment les cancers associés à un antigène tumoral tels que le mélanome, ainsi que des compositions pharmaceutiques comprenant certains de ces composés.

ONLY FOR INFORMATION

Codes used to identify the PCT member States on the flyleaves of the brochures in which international applications made under the PCT are published.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia-Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	Former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Vietnam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Ivory Coast	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						